clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00025337 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | United States of America | Q30 |
P582 | end time | 2007-04-01 | |
P1050 | medical condition | adenocarcinoma | Q356033 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 880 | |
P4844 | research intervention | calcium oxalate | Q412399 |
bevacizumab | Q413299 | ||
fluorouracil | Q238512 | ||
leucovorin calcium | Q27077063 | ||
immunological antineoplastic agent | Q50429626 | ||
P6153 | research site | Eastern Cooperative Oncology Group | Q5330089 |
P580 | start time | 2001-09-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer |
Search more.